ActivX Biosciences Announces Expansion of Strategic Collaboration Agreement with Pfizer Inc. with Multiple Discovery and Developmental Stage Projects
February 9, 2005
New York, NY and La Jolla, CA; February 9, 2005 – Pfizer Inc. (NYSE: PFE) and ActivX Biosciences, Inc., a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd. (TSE: 4560), announced today they have entered into a strategic collaborative agreement encompassing multiple projects ranging from discovery to developmental stage programs across multiple research sites of Pfizer’s Global Research and Development organization.
Under the terms of the agreement, ActivX will apply its novel chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, proteomic profiling, compound selectivity and biological activity, and mechanisms of toxicity.
“We are delighted that Pfizer is expanding its relationship with ActivX based on the success of our initial collaboration,” stated Dr. John W. Kozarich, Chairman and President at ActivX. “The geographical scope of this expansion within Pfizer and the pharmaceutical breadth of the new programs under this agreement are solid indicators of the power and applicability of the ActivX technology,” he added.
“Over the past year, ActivX has provided important initial data on the utility of its technology to impact Pfizer programs,” commented Dr. John LaMattina, President of Global Research & Development at Pfizer. “This expanded, multi-site collaboration will permit Pfizer to fully explore the technology’s scope and value in a variety of R&D settings,” Dr. LaMattina further added.
Financial terms of this transaction include an upfront technology access fee along with research support payments by Pfizer.
About ActivX Biosciences, Inc.
ActivX Biosciences, Inc. (www.activx.com), a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., in La Jolla, California, is applying proprietary chemical technologies and high-throughput protein analysis to the drug discovery process. By focusing on functional proteins, ActivX addresses disease mechanisms directly, in contrast to approaches such as expression profiling, in which the measured analyte is several steps removed from the site of drug action. ActivX and its partners are using its proprietary technology to address critical challenges in drug discovery, including selectivity profiling of candidate drug molecules across whole protein families in biological samples to guide their medicinal chemistry optimization; identifying novel drug targets and biomarkers; and characterizing off-target activities of candidate and established drugs to understand the basis for their efficacy and toxicity.
About Pfizer Inc.
Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.
Pfizer Inc. DISCLOSURE NOTICE: The information contained in this document is as of February 9, 2005. Pfizer assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.
This document contains forward-looking information about the development of products that involves inherent uncertainties. The success of the research for and development of such products, the speed with which regulatory authorizations for and the launch of such products may be achieved, and competitive developments, among other factors, could affect the commercial potential of such products. A further list and description of these risks, uncertainties and other matters can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2003, and in its periodic reports on Forms 10-Q and 8-K.
# # #
Contact: John W. Kozarich
ActivX Biosciences
858.558.5558
| © 2007 ActivX Biosciences, Inc. A wholly owned subsidiary of Kyorin Pharmaceutical Co, Ltd. |  info@activx.com |